Lawyers at DLA Piper are defending Novo Nordisk in a product liability action involving the company’s blockbuster weight loss drug Wegovy. The lawsuit, filed Sept. 19 by Motley Rice in Philadelphia County, claims that the drugmaker downplayed or failed to disclose known side effects of Wegovy, including gastroparesis, gastroenteritis, intestinal blockage and malnutrition. DLA Piper removed the matter to Pennsylvania Eastern District Court on Oct. 10. The case is 2:23-cv-0392, Miller v. Novo Nordisk et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]